LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between BIOCRYST PHARMACEUTICALS, INC. and SHIONOGI & CO., LTD. Dated as of February 28, 2007License, Development and Commercialization Agreement • May 10th, 2007 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of February 28, 2007 by and between BIOCRYST PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware having offices at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (“BioCryst”), and SHIONOGI & CO., LTD., a corporation organized and existing under the laws of the Japan having offices at 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan (“Shionogi”). BioCryst and Shionogi are each referred to herein by name or individually as a “Party” or collectively as the “Parties.”
BIOCRYST PHARMACEUTICALS, INC. 2190 PARKWAY LAKE DRIVE BIRMINGHAM, AL 35244 205-444-4600 205-444-4640 FAX www.biocryst.comLetter Agreement • May 10th, 2007 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Alabama
This letter agreement (the “Agreement”) will serve to confirm our agreement with respect to the terms and conditions of your employment by BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst” or the “Company”).
